Christopher Haqq
Overview
Christopher Haqq received an average of $918K in total compensation, including $477K in salary, at Elicio Therapeutics between 2022 and 2023. Christopher Haqq also received an average of $2M at Atara Biotherapeutics from 2013 to 2016.
- 2023
- 2022
- 2016
- 2015
- 2014
- 2013
Elicio TherapeuticsExecutive Vice President, Head of Research and Development and Chief Medical Officer
Elicio TherapeuticsExecutive Vice President, Head of Research and Development and Chief Medical Officer
Atara BiotherapeuticsEVP, R&D and Chief Scientific Officer
Atara BiotherapeuticsEVP, R&D and Chief Scientific Officer
Atara BiotherapeuticsChief Medical Officer
Atara BiotherapeuticsChief Medical Officer
Source: SEC filings on September 27, 2024, April 24, 2017, April 29, 2016, and April 28, 2015.
Related executives
We found 14 more executives who work or worked at Elicio Therapeutics and Atara Biotherapeutics.
Jay Venkatesan
Elicio Therapeutics
Chief Executive Officer
Jennifer Rhodes
Elicio Therapeutics
General Counsel
Brian Piekos
Elicio Therapeutics
Chief Financial Officer
Robert Connelly
Elicio Therapeutics
Chief Executive Officer
Isaac Ciechanover
Atara Biotherapeutics
Chief Executive Officer
Pascal Touchon
Atara Biotherapeutics
Chief Executive Officer
Dietmar Berger
Atara Biotherapeutics
Former Global Head of Research & Development
Joseph Newell
Atara Biotherapeutics